Global Non-Small Cell Lung Cancer

Global Non-Small Cell Lung Cancer Market Research Report: Forecast (2022-2027)

By Diagnosis (Blood & Urine Tests, Imaging, Biopsy, Sputum Cytology, Bronchoscopy), By Cancer Type (Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), Adenocarcinoma), By Treatment (Surgery, C Read more

  • Healthcare
  • Jun 2022
  • 189
  • HC22095

Market Definition

Non-Small Cell Lung Cancer (NSCLC) is the most common & epithelial type of lung cancer that occurs in different forms, viz., Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), & Adenocarcinoma. While most cases show cigarette smoking as the prime cause of NSCLC, there are many incidences of Adenocarcinoma seen in patients who have never smoked.

As the prevalence of lung cancers is rising worldwide, the demand for their diagnosis & treatments is also surging rapidly, which, in turn, is compelling governments & leading biopharma companies to boost drug developments & distributions in order to cater to the unmet patient needs for efficient & safe NSCLC treatments.

Market Insights

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide. 

Observing the growing influx of NSCLC patients globally, governments of different countries are investing massively in the healthcare sector to strengthen the oncology department, including the NSCLC, and encourage the leading biopharmaceutical companies to discover novel therapeutics with enhanced efficacy & safety. As a result, the expansion of various players and the emergence of local companies are seen extensively worldwide. 

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR 11.2%
Regions Covered North America: The US, Canada, Mexico
South America: Brazil, Rest of South America
Europe: Germany, The UK, France, Spain, Italy, Rest of Europe
Asia-Pacific: China, Japan, India, South Korea, Rest of Asia Pacific
Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa
Key Companies Profiled Allergan (AbbVie), AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb, Eisai Co., Ltd, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Other
Unit Denominations USD Million/Billion

 

Additionally, growing awareness among people about the availability of diagnosis & various treatments for NSCLC through government engagement in campaigns, advertisements, etc., i.e., portraying a rising patient pool across different countries, is further augmenting the overall market growth. 

The leading biotechnology & pharmaceutical companies like Pfizer Inc. are developing & introducing sophisticated targeted therapies like Vizimpra & Lorbrena for NSCLC patients, i.e., another crucial aspect projecting remunerative prospects for the Global Non-Small Cell Lung Cancer (NSCLC) Market through 2027.

Market Segmentation

Based on the Cancer Type:

  • Squamous Cell Carcinoma (SCC)
  • Large Cell Carcinoma (LCC)
  • Adenocarcinoma

Of all cancer types, adenocarcinoma is anticipated to dominate the Global Non-Small Cell Lung Cancer (NSCLC) Market with the largest share during 2022-27. It attributes principally to higher cases of adenocarcinoma than other types of NSCLC, i.e., propagating the need for its effective diagnosis & treatment.

Adenocarcinoma generally occurs in the outer region of the lungs, grows slower than other lung cancers, and is more likely to be diagnosed in its early stage. It is seen commonly in females & non-smoker males. Apart from this, the younger generation is among the prominent patients.

Governments of different countries are making active efforts to spread awareness of the availability of diagnosis & treatment and the need to restrain habits like smoking. With rapid developments in medical science, there are various treatments for NSCLC, depending upon the patient's health condition:

  • Surgery: The treatment is one of the prominent therapies performed whenever possible to remove the Adenocarcinoma tumor from the lungs. However, it is done only after determining the tumor location & size and overall health & pulmonary functions of patients. 
  • Radiation Therapy: In this treatment, high-energy rays are targeted directly at tumor cells to destroy them or curb their growth. These radiations also include external beam radiation therapy to send radiation from outside the body into the affected area. Another method, Brachytherapy, is when the radiation is sent internally by injecting a radioactive substance with a bronchoscope directly into the tumor or near the area. This treatment is also done post-surgery to prevent the possibility of reoccurrence.
  • Targeted Therapy: It is an extensively used treatment for patients with adenocarcinoma NSCLC since it less damages the healthy cells than other therapies. Monoclonal antibodies, Tyrosine Kinase Inhibitors (TKIs), and mammalian Target of Rapamycin (mTOR) inhibitors are various Targeted drugs that help destroy specific cancer cells. 

Based on the Treatment:

  • Surgery
  • Chemotherapy
  • Immunotherapy
    • Immune Checkpoint Inhibitors
      • PD-1/PD-L1 Inhibitors
      • CTLA-4 Inhibitor
  • Radiation Therapy
    • External Beam Radiation Therapy
    • Brachytherapy (Internal Radiation Therapy)
  • Radiofrequency Ablation (RFA)
  • Targeted Therapy

Of them all, immunotherapy is likely to contribute significantly to the overall market expansion through 2027. It owes principally to the growing awareness among people about its benefits like better efficacy & safety. Immunotherapy drugs strengthen & direct the immune system of the patient to identify & kill the cancer cells effectively. Immune checkpoint inhibitors are the major category of immunotherapy drugs used extensively in NSCLC treatment, which turns the immune system on for targeting the cancer cells directly & attacking potentially harmful agents in the body.

If the immune response begins to affect healthy tissues, turning off checkpoint inhibitors can prevent the damage. Programmed Cell Death Protein 1/Ligand 1 (PD-1/PD-L1) & Cytotoxic T Lymphocyte-Associated Antigen (CTLA-4) are a few commonly used immune checkpoint inhibitors.

The application of immunotherapy, combined with other treatments like surgery, chemotherapy, & radiation therapy, among others, is demonstrating positive outcomes in NSCLC patients worldwide and is an emerging trend globally. Nonetheless, with the escalating prevalence of NSCLC, the availability of treatments like immunotherapy in multiple options is becoming easy and playing a prominent role in driving the global market.

Regional Landscape

Geographically, the Global Non-Small Cell Lung Cancer (NSCLC) Market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Of all regions globally, North America acquired the largest share in the Non-Small Cell Lung Cancer (NSCLC) Market in previous years, and the same trend is likely during 2022-27. It owes principally to the high rate of patients with lung cancer, especially NSCLC, i.e., a prominent cause of death across different countries in the region. It, in turn, is instigating governments to invest substantially in developing new medications & bring innovations to the existing ones to cater to the high unmet needs of patients for treatments & offer them positive outcomes.

Besides, the increasing population of smokers and high exposure to toxins like asbestos and elements of air pollution are the other aspects causing NSCLC among people across North America, i.e., leading to increasing rates of diagnosis & therapeutics and, in turn, stimulating the regional market growth.

On the other hand, Asia-Pacific is anticipated to demonstrate the fastest market growth in the coming years, principally due to the mounting focus of governments of different countries in the region on developing the robust healthcare infrastructure, especially oncology, including NSCLC cancer.

In Asia-Pacific, countries like India & China project lucrative opportunities for the leading players due to massive healthcare expenditure & favorable policies for the development & clinical trials of NSCLC therapeutics. It, in turn, would showcase the active participation of the leading biopharma companies in contributing to the fastest growth of the Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market through 2027. 

Key Questions Answered in the Market Research Report:

  1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Non-Small Cell Lung Cancer (NSCLC) Market?
  2. What are the region-wise industry size, growth drivers, and challenges?
  3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Non-Small Cell Lung Cancer (NSCLC) Market?
  4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Non-Small Cell Lung Cancer (NSCLC) Market based on the competitive benchmarking matrix?
  5. What are the key results derived from surveys conducted during the Global Non-Small Cell Lung Cancer (NSCLC) Market study?

Frequently Asked Questions

A. The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during 2022-27.

A. The growing incidence of NSCLC patients and increasing funding by governments on R&D of novel drugs for NSLC treatment are the prominent factors projected to drive the Global Non-Small Cell Lung Cancer (NSCLC) Market through 2027.

A. The mounting adoption of a combination of therapies like surgery, immunotherapy, radiation, etc., is the key trend in the Global Non-Small Cell Lung Cancer (NSCLC) Market.

A. Combination therapies are anticipated to emerge as an area of remunerative opportunities for the leading players in the Global Non-Small Cell Lung Cancer (NSCLC) Market over the forecast years.

A. Globally, North America is projected to acquire a prominent share in the Non-Small Cell Lung Cancer (NSCLC) Market through 2027.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Non-Small Cell Lung Cancer (NSCLC) Market Trends & Insights
  4. Global Non-Small Cell Lung Cancer (NSCLC) Market Regulation & Policy, By Country
  5. Global Non-Small Cell Lung Cancer (NSCLC) Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Non-Small Cell Lung Cancer (NSCLC) Market Hotspot and Opportunities
  7. Global Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Blood & Urine Tests
        2. Imaging
        3. Biopsy
        4. Sputum Cytology
        5. Bronchoscopy
      2. By Cancer Type
        1. Squamous Cell Carcinoma (SCC)
        2. Large Cell Carcinoma (LCC)
        3. Adenocarcinoma
      3. By Treatment
        1. Surgery
        2. Chemotherapy
        3. Immunotherapy
          1. Immune Checkpoint Inhibitors
            1. PD-1/PD-L1 Inhibitors
            2. CTLA-4 Inhibitor
        4. Radiation Therapy
          1. External Beam Radiation Therapy
          2. Brachytherapy (Internal Radiation Therapy)
        5. Radiofrequency Ablation (RFA)
        6. Targeted Therapy
      4. By End-User
        1. Hospitals
        2. Cancer Centers
        3. Others (Ambulatory Surgery Centers, etc.)
      5. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      6. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia Pacific
  13. Global Non-Small Cell Lung Cancer (NSCLC) Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. Allergan (AbbVie)
      2. AstraZeneca PLC
      3. Boehringer Ingelheim
      4. Bristol Myers Squibb
      5. Eisai Co., Ltd.
      6. Eli Lilly and Company
      7. GlaxoSmithKline PLC
      8. F. Hoffmann-La Roche AG
      9. Merck & Co., Inc.
      10. Novartis International AG
      11. Pfizer Inc.
      12. Sanofi S.A.
      13. Others
  15. Disclaimer
Non-Small Cell Lung Cancer (NSCLC) Market Segmentation